PCI Biotech to present clinical data on its phase I/II trial in bile duct cancer at The International Liver Congress 2017

Oslo, Norway, April 6, 2017 - PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announces that clinical data, including emerging interim survival data, from the phase I part of the study in bile duct cancer will be presented during a poster session at The International Liver Congress 2017 - the annual meeting of the European Association for the Study of the Liver (EASL).

The event is taking place in Amsterdam, the Netherlands, from 19 to 23 April 2017 and PCI Biotech will present a poster on 21 April 2017. The poster will be presented by Dr. Richard Sturgess, Coordinating Investigator of PCI Biotech's study in inoperable bile duct cancer.

Key information from the poster will be released in conjunction with the poster presentation.

About PCI Biotech

PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform.  PCI is applied to three distinct anticancer paradigms: fimaCHEM (enhancement of chemotherapeutics for localised treatment of cancer), fimaVACC (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company's lead fimaCHEM programme consists of a clinical Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVACC applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway. www.pcibiotech.com      
Ronny Skuggedal, CFO, rs@pcibiotech.com , Mobile: +47 9400 5757.

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.